nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—UGT2B7—Epirubicin—liver cancer	0.138	0.24	CbGbCtD
Ezetimibe—UGT1A1—Sorafenib—liver cancer	0.105	0.182	CbGbCtD
Ezetimibe—ABCC3—Doxorubicin—liver cancer	0.085	0.148	CbGbCtD
Ezetimibe—ABCC2—Sorafenib—liver cancer	0.0637	0.111	CbGbCtD
Ezetimibe—ABCG2—Sorafenib—liver cancer	0.0576	0.0999	CbGbCtD
Ezetimibe—ABCC2—Doxorubicin—liver cancer	0.0386	0.0671	CbGbCtD
Ezetimibe—ABCG2—Doxorubicin—liver cancer	0.0349	0.0606	CbGbCtD
Ezetimibe—ABCC2—bile canaliculus—liver cancer	0.0265	0.194	CbGeAlD
Ezetimibe—ABCB1—Sorafenib—liver cancer	0.0208	0.036	CbGbCtD
Ezetimibe—ANPEP—bile—liver cancer	0.016	0.117	CbGeAlD
Ezetimibe—ABCG5—gall bladder—liver cancer	0.0144	0.105	CbGeAlD
Ezetimibe—ABCG8—gall bladder—liver cancer	0.0128	0.0937	CbGeAlD
Ezetimibe—ABCB1—Doxorubicin—liver cancer	0.0126	0.0219	CbGbCtD
Ezetimibe—CYP3A4—Sorafenib—liver cancer	0.0124	0.0216	CbGbCtD
Ezetimibe—ABCC3—bile duct—liver cancer	0.0104	0.0757	CbGeAlD
Ezetimibe—ABCC2—bile duct—liver cancer	0.00828	0.0605	CbGeAlD
Ezetimibe—CYP3A4—Doxorubicin—liver cancer	0.00754	0.0131	CbGbCtD
Ezetimibe—ABCC2—bile—liver cancer	0.00636	0.0465	CbGeAlD
Ezetimibe—UGT2B15—gall bladder—liver cancer	0.00539	0.0394	CbGeAlD
Ezetimibe—SOAT1—gall bladder—liver cancer	0.00463	0.0339	CbGeAlD
Ezetimibe—ANPEP—gall bladder—liver cancer	0.00443	0.0324	CbGeAlD
Ezetimibe—ABCG5—liver—liver cancer	0.00422	0.0308	CbGeAlD
Ezetimibe—NPC1L1—liver—liver cancer	0.00397	0.029	CbGeAlD
Ezetimibe—ABCG8—liver—liver cancer	0.00376	0.0275	CbGeAlD
Ezetimibe—ANPEP—embryo—liver cancer	0.00281	0.0205	CbGeAlD
Ezetimibe—Cholecystitis—Sorafenib—liver cancer	0.00243	0.0265	CcSEcCtD
Ezetimibe—ABCC3—gall bladder—liver cancer	0.00221	0.0161	CbGeAlD
Ezetimibe—Interstitial lung disease—Sorafenib—liver cancer	0.00197	0.0215	CcSEcCtD
Ezetimibe—UGT1A3—liver—liver cancer	0.00168	0.0123	CbGeAlD
Ezetimibe—Neoplasm malignant—Sorafenib—liver cancer	0.00163	0.0178	CcSEcCtD
Ezetimibe—UGT2B15—liver—liver cancer	0.00158	0.0115	CbGeAlD
Ezetimibe—Rhabdomyolysis—Sorafenib—liver cancer	0.00157	0.0172	CcSEcCtD
Ezetimibe—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.00154	0.0169	CcSEcCtD
Ezetimibe—Bone disorder—Sorafenib—liver cancer	0.00154	0.0169	CcSEcCtD
Ezetimibe—Drug interaction—Sorafenib—liver cancer	0.0015	0.0164	CcSEcCtD
Ezetimibe—SOAT1—liver—liver cancer	0.00136	0.00993	CbGeAlD
Ezetimibe—ANPEP—liver—liver cancer	0.0013	0.00949	CbGeAlD
Ezetimibe—Hepatic failure—Sorafenib—liver cancer	0.00113	0.0123	CcSEcCtD
Ezetimibe—Pain in extremity—Sorafenib—liver cancer	0.00101	0.0111	CcSEcCtD
Ezetimibe—UGT2B7—liver—liver cancer	0.000965	0.00705	CbGeAlD
Ezetimibe—Breast disorder—Sorafenib—liver cancer	0.000914	0.00999	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00091	0.00995	CcSEcCtD
Ezetimibe—Nasopharyngitis—Sorafenib—liver cancer	0.000904	0.00989	CcSEcCtD
Ezetimibe—Gastritis—Sorafenib—liver cancer	0.000895	0.00978	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000892	0.00975	CcSEcCtD
Ezetimibe—Pancreatitis—Sorafenib—liver cancer	0.000857	0.00937	CcSEcCtD
Ezetimibe—Transaminases increased—Epirubicin—liver cancer	0.000846	0.00925	CcSEcCtD
Ezetimibe—UGT1A1—liver—liver cancer	0.000821	0.00599	CbGeAlD
Ezetimibe—Erectile dysfunction—Sorafenib—liver cancer	0.000805	0.0088	CcSEcCtD
Ezetimibe—Transaminases increased—Doxorubicin—liver cancer	0.000783	0.00856	CcSEcCtD
Ezetimibe—Infestation—Sorafenib—liver cancer	0.000779	0.00852	CcSEcCtD
Ezetimibe—Infestation NOS—Sorafenib—liver cancer	0.000779	0.00852	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Sorafenib—liver cancer	0.000764	0.00835	CcSEcCtD
Ezetimibe—Jaundice—Sorafenib—liver cancer	0.00076	0.0083	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Sorafenib—liver cancer	0.000737	0.00806	CcSEcCtD
Ezetimibe—Connective tissue disorder—Sorafenib—liver cancer	0.000687	0.00752	CcSEcCtD
Ezetimibe—SLCO1B1—liver—liver cancer	0.000683	0.00499	CbGeAlD
Ezetimibe—Erythema multiforme—Sorafenib—liver cancer	0.000661	0.00723	CcSEcCtD
Ezetimibe—Flushing—Sorafenib—liver cancer	0.000649	0.0071	CcSEcCtD
Ezetimibe—ABCC3—liver—liver cancer	0.000648	0.00473	CbGeAlD
Ezetimibe—Angiopathy—Sorafenib—liver cancer	0.000635	0.00694	CcSEcCtD
Ezetimibe—Immune system disorder—Sorafenib—liver cancer	0.000632	0.00691	CcSEcCtD
Ezetimibe—Mediastinal disorder—Sorafenib—liver cancer	0.00063	0.00689	CcSEcCtD
Ezetimibe—Alopecia—Sorafenib—liver cancer	0.000618	0.00676	CcSEcCtD
Ezetimibe—Mental disorder—Sorafenib—liver cancer	0.000613	0.0067	CcSEcCtD
Ezetimibe—Malnutrition—Sorafenib—liver cancer	0.000609	0.00666	CcSEcCtD
Ezetimibe—Erythema—Sorafenib—liver cancer	0.000609	0.00666	CcSEcCtD
Ezetimibe—Neoplasm malignant—Epirubicin—liver cancer	0.000603	0.00659	CcSEcCtD
Ezetimibe—Muscle spasms—Sorafenib—liver cancer	0.000585	0.0064	CcSEcCtD
Ezetimibe—Viral infection—Epirubicin—liver cancer	0.00057	0.00623	CcSEcCtD
Ezetimibe—Bone disorder—Epirubicin—liver cancer	0.00057	0.00623	CcSEcCtD
Ezetimibe—Anaemia—Sorafenib—liver cancer	0.000563	0.00615	CcSEcCtD
Ezetimibe—Neoplasm malignant—Doxorubicin—liver cancer	0.000558	0.0061	CcSEcCtD
Ezetimibe—Angioedema—Sorafenib—liver cancer	0.000556	0.00608	CcSEcCtD
Ezetimibe—Cough—Sorafenib—liver cancer	0.000531	0.00581	CcSEcCtD
Ezetimibe—Inflammation—Epirubicin—liver cancer	0.000531	0.0058	CcSEcCtD
Ezetimibe—Bone disorder—Doxorubicin—liver cancer	0.000527	0.00577	CcSEcCtD
Ezetimibe—Viral infection—Doxorubicin—liver cancer	0.000527	0.00577	CcSEcCtD
Ezetimibe—Hypertension—Sorafenib—liver cancer	0.000526	0.00575	CcSEcCtD
Ezetimibe—Neck pain—Epirubicin—liver cancer	0.000521	0.0057	CcSEcCtD
Ezetimibe—Myalgia—Sorafenib—liver cancer	0.000518	0.00567	CcSEcCtD
Ezetimibe—Arthralgia—Sorafenib—liver cancer	0.000518	0.00567	CcSEcCtD
Ezetimibe—ABCC2—liver—liver cancer	0.000518	0.00378	CbGeAlD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000515	0.00563	CcSEcCtD
Ezetimibe—Hepatocellular injury—Epirubicin—liver cancer	0.000515	0.00563	CcSEcCtD
Ezetimibe—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000515	0.00563	CcSEcCtD
Ezetimibe—Dry mouth—Sorafenib—liver cancer	0.000507	0.00554	CcSEcCtD
Ezetimibe—Anaphylactic shock—Sorafenib—liver cancer	0.000497	0.00543	CcSEcCtD
Ezetimibe—Infection—Sorafenib—liver cancer	0.000494	0.0054	CcSEcCtD
Ezetimibe—Inflammation—Doxorubicin—liver cancer	0.000491	0.00537	CcSEcCtD
Ezetimibe—Flunarizine—CYP1A1—liver cancer	0.000488	0.517	CrCbGaD
Ezetimibe—Nervous system disorder—Sorafenib—liver cancer	0.000487	0.00533	CcSEcCtD
Ezetimibe—Thrombocytopenia—Sorafenib—liver cancer	0.000487	0.00532	CcSEcCtD
Ezetimibe—Skin disorder—Sorafenib—liver cancer	0.000483	0.00528	CcSEcCtD
Ezetimibe—Neck pain—Doxorubicin—liver cancer	0.000482	0.00527	CcSEcCtD
Ezetimibe—Hepatocellular injury—Doxorubicin—liver cancer	0.000476	0.00521	CcSEcCtD
Ezetimibe—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000476	0.00521	CcSEcCtD
Ezetimibe—Pimozide—CYP2E1—liver cancer	0.000456	0.483	CrCbGaD
Ezetimibe—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000453	0.00495	CcSEcCtD
Ezetimibe—Dyspnoea—Sorafenib—liver cancer	0.000443	0.00484	CcSEcCtD
Ezetimibe—Dyspepsia—Sorafenib—liver cancer	0.000437	0.00478	CcSEcCtD
Ezetimibe—Decreased appetite—Sorafenib—liver cancer	0.000432	0.00472	CcSEcCtD
Ezetimibe—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00043	0.0047	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Sorafenib—liver cancer	0.000429	0.00469	CcSEcCtD
Ezetimibe—Fatigue—Sorafenib—liver cancer	0.000428	0.00468	CcSEcCtD
Ezetimibe—Photosensitivity—Epirubicin—liver cancer	0.000426	0.00465	CcSEcCtD
Ezetimibe—Constipation—Sorafenib—liver cancer	0.000425	0.00465	CcSEcCtD
Ezetimibe—Pain—Sorafenib—liver cancer	0.000425	0.00465	CcSEcCtD
Ezetimibe—Hepatic failure—Epirubicin—liver cancer	0.000416	0.00455	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Sorafenib—liver cancer	0.000406	0.00444	CcSEcCtD
Ezetimibe—ABCB1—embryo—liver cancer	0.000402	0.00294	CbGeAlD
Ezetimibe—Hot flush—Epirubicin—liver cancer	0.000399	0.00437	CcSEcCtD
Ezetimibe—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000398	0.00435	CcSEcCtD
Ezetimibe—Menopausal symptoms—Epirubicin—liver cancer	0.000396	0.00433	CcSEcCtD
Ezetimibe—Urticaria—Sorafenib—liver cancer	0.000395	0.00432	CcSEcCtD
Ezetimibe—Photosensitivity—Doxorubicin—liver cancer	0.000394	0.00431	CcSEcCtD
Ezetimibe—Abdominal pain—Sorafenib—liver cancer	0.000393	0.0043	CcSEcCtD
Ezetimibe—Body temperature increased—Sorafenib—liver cancer	0.000393	0.0043	CcSEcCtD
Ezetimibe—Hepatic failure—Doxorubicin—liver cancer	0.000385	0.00421	CcSEcCtD
Ezetimibe—ABCG2—liver—liver cancer	0.000377	0.00276	CbGeAlD
Ezetimibe—Pain in extremity—Epirubicin—liver cancer	0.000374	0.00409	CcSEcCtD
Ezetimibe—Hot flush—Doxorubicin—liver cancer	0.00037	0.00404	CcSEcCtD
Ezetimibe—Menopausal symptoms—Doxorubicin—liver cancer	0.000366	0.00401	CcSEcCtD
Ezetimibe—Hypersensitivity—Sorafenib—liver cancer	0.000366	0.004	CcSEcCtD
Ezetimibe—Asthenia—Sorafenib—liver cancer	0.000357	0.0039	CcSEcCtD
Ezetimibe—Pruritus—Sorafenib—liver cancer	0.000352	0.00384	CcSEcCtD
Ezetimibe—Pain in extremity—Doxorubicin—liver cancer	0.000346	0.00378	CcSEcCtD
Ezetimibe—Liver function test abnormal—Epirubicin—liver cancer	0.000345	0.00377	CcSEcCtD
Ezetimibe—Diarrhoea—Sorafenib—liver cancer	0.00034	0.00372	CcSEcCtD
Ezetimibe—Breast disorder—Epirubicin—liver cancer	0.000338	0.00369	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000336	0.00368	CcSEcCtD
Ezetimibe—Nasopharyngitis—Epirubicin—liver cancer	0.000334	0.00365	CcSEcCtD
Ezetimibe—Gastritis—Epirubicin—liver cancer	0.000331	0.00362	CcSEcCtD
Ezetimibe—Muscular weakness—Epirubicin—liver cancer	0.00033	0.0036	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00033	0.0036	CcSEcCtD
Ezetimibe—Dizziness—Sorafenib—liver cancer	0.000329	0.00359	CcSEcCtD
Ezetimibe—Influenza—Epirubicin—liver cancer	0.000323	0.00353	CcSEcCtD
Ezetimibe—Eosinophilia—Epirubicin—liver cancer	0.00032	0.0035	CcSEcCtD
Ezetimibe—Liver function test abnormal—Doxorubicin—liver cancer	0.000319	0.00349	CcSEcCtD
Ezetimibe—Pancreatitis—Epirubicin—liver cancer	0.000317	0.00346	CcSEcCtD
Ezetimibe—Vomiting—Sorafenib—liver cancer	0.000316	0.00345	CcSEcCtD
Ezetimibe—Rash—Sorafenib—liver cancer	0.000313	0.00343	CcSEcCtD
Ezetimibe—Dermatitis—Sorafenib—liver cancer	0.000313	0.00342	CcSEcCtD
Ezetimibe—Breast disorder—Doxorubicin—liver cancer	0.000312	0.00342	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000311	0.0034	CcSEcCtD
Ezetimibe—Headache—Sorafenib—liver cancer	0.000311	0.0034	CcSEcCtD
Ezetimibe—Nasopharyngitis—Doxorubicin—liver cancer	0.000309	0.00338	CcSEcCtD
Ezetimibe—Gastritis—Doxorubicin—liver cancer	0.000306	0.00335	CcSEcCtD
Ezetimibe—Muscular weakness—Doxorubicin—liver cancer	0.000305	0.00333	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000305	0.00333	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Epirubicin—liver cancer	0.0003	0.00328	CcSEcCtD
Ezetimibe—Influenza—Doxorubicin—liver cancer	0.000299	0.00327	CcSEcCtD
Ezetimibe—Eosinophilia—Doxorubicin—liver cancer	0.000296	0.00323	CcSEcCtD
Ezetimibe—Nausea—Sorafenib—liver cancer	0.000295	0.00323	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Epirubicin—liver cancer	0.000295	0.00322	CcSEcCtD
Ezetimibe—Pancreatitis—Doxorubicin—liver cancer	0.000293	0.0032	CcSEcCtD
Ezetimibe—Infestation—Epirubicin—liver cancer	0.000288	0.00315	CcSEcCtD
Ezetimibe—Infestation NOS—Epirubicin—liver cancer	0.000288	0.00315	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Epirubicin—liver cancer	0.000282	0.00309	CcSEcCtD
Ezetimibe—Jaundice—Epirubicin—liver cancer	0.000281	0.00307	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000278	0.00304	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Doxorubicin—liver cancer	0.000273	0.00298	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Epirubicin—liver cancer	0.000272	0.00298	CcSEcCtD
Ezetimibe—Sinusitis—Epirubicin—liver cancer	0.00027	0.00295	CcSEcCtD
Ezetimibe—Infestation NOS—Doxorubicin—liver cancer	0.000266	0.00291	CcSEcCtD
Ezetimibe—Infestation—Doxorubicin—liver cancer	0.000266	0.00291	CcSEcCtD
Ezetimibe—CYP3A4—liver—liver cancer	0.000263	0.00192	CbGeAlD
Ezetimibe—Neuropathy peripheral—Doxorubicin—liver cancer	0.000261	0.00286	CcSEcCtD
Ezetimibe—Jaundice—Doxorubicin—liver cancer	0.00026	0.00284	CcSEcCtD
Ezetimibe—Hepatitis—Epirubicin—liver cancer	0.000259	0.00283	CcSEcCtD
Ezetimibe—Pharyngitis—Epirubicin—liver cancer	0.000257	0.00281	CcSEcCtD
Ezetimibe—Oedema peripheral—Epirubicin—liver cancer	0.000255	0.00278	CcSEcCtD
Ezetimibe—Connective tissue disorder—Epirubicin—liver cancer	0.000254	0.00278	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Doxorubicin—liver cancer	0.000252	0.00276	CcSEcCtD
Ezetimibe—Sinusitis—Doxorubicin—liver cancer	0.00025	0.00273	CcSEcCtD
Ezetimibe—Erythema multiforme—Epirubicin—liver cancer	0.000244	0.00267	CcSEcCtD
Ezetimibe—Flushing—Epirubicin—liver cancer	0.00024	0.00262	CcSEcCtD
Ezetimibe—Hepatitis—Doxorubicin—liver cancer	0.000239	0.00262	CcSEcCtD
Ezetimibe—Pharyngitis—Doxorubicin—liver cancer	0.000237	0.0026	CcSEcCtD
Ezetimibe—Oedema peripheral—Doxorubicin—liver cancer	0.000236	0.00258	CcSEcCtD
Ezetimibe—Connective tissue disorder—Doxorubicin—liver cancer	0.000235	0.00257	CcSEcCtD
Ezetimibe—Angiopathy—Epirubicin—liver cancer	0.000235	0.00256	CcSEcCtD
Ezetimibe—Immune system disorder—Epirubicin—liver cancer	0.000233	0.00255	CcSEcCtD
Ezetimibe—Mediastinal disorder—Epirubicin—liver cancer	0.000233	0.00255	CcSEcCtD
Ezetimibe—Alopecia—Epirubicin—liver cancer	0.000228	0.0025	CcSEcCtD
Ezetimibe—Mental disorder—Epirubicin—liver cancer	0.000226	0.00248	CcSEcCtD
Ezetimibe—Erythema multiforme—Doxorubicin—liver cancer	0.000226	0.00247	CcSEcCtD
Ezetimibe—Erythema—Epirubicin—liver cancer	0.000225	0.00246	CcSEcCtD
Ezetimibe—Malnutrition—Epirubicin—liver cancer	0.000225	0.00246	CcSEcCtD
Ezetimibe—Flushing—Doxorubicin—liver cancer	0.000222	0.00243	CcSEcCtD
Ezetimibe—Flatulence—Epirubicin—liver cancer	0.000222	0.00242	CcSEcCtD
Ezetimibe—Back pain—Epirubicin—liver cancer	0.000218	0.00238	CcSEcCtD
Ezetimibe—Angiopathy—Doxorubicin—liver cancer	0.000217	0.00237	CcSEcCtD
Ezetimibe—Muscle spasms—Epirubicin—liver cancer	0.000216	0.00237	CcSEcCtD
Ezetimibe—Immune system disorder—Doxorubicin—liver cancer	0.000216	0.00236	CcSEcCtD
Ezetimibe—Mediastinal disorder—Doxorubicin—liver cancer	0.000216	0.00236	CcSEcCtD
Ezetimibe—Alopecia—Doxorubicin—liver cancer	0.000211	0.00231	CcSEcCtD
Ezetimibe—Mental disorder—Doxorubicin—liver cancer	0.00021	0.00229	CcSEcCtD
Ezetimibe—Ill-defined disorder—Epirubicin—liver cancer	0.000209	0.00228	CcSEcCtD
Ezetimibe—Malnutrition—Doxorubicin—liver cancer	0.000208	0.00228	CcSEcCtD
Ezetimibe—Erythema—Doxorubicin—liver cancer	0.000208	0.00228	CcSEcCtD
Ezetimibe—Anaemia—Epirubicin—liver cancer	0.000208	0.00227	CcSEcCtD
Ezetimibe—Flatulence—Doxorubicin—liver cancer	0.000205	0.00224	CcSEcCtD
Ezetimibe—Malaise—Epirubicin—liver cancer	0.000203	0.00222	CcSEcCtD
Ezetimibe—Back pain—Doxorubicin—liver cancer	0.000201	0.0022	CcSEcCtD
Ezetimibe—Muscle spasms—Doxorubicin—liver cancer	0.0002	0.00219	CcSEcCtD
Ezetimibe—Palpitations—Epirubicin—liver cancer	0.000199	0.00217	CcSEcCtD
Ezetimibe—Cough—Epirubicin—liver cancer	0.000196	0.00215	CcSEcCtD
Ezetimibe—Hypertension—Epirubicin—liver cancer	0.000194	0.00212	CcSEcCtD
Ezetimibe—Ill-defined disorder—Doxorubicin—liver cancer	0.000193	0.00211	CcSEcCtD
Ezetimibe—Anaemia—Doxorubicin—liver cancer	0.000192	0.0021	CcSEcCtD
Ezetimibe—Arthralgia—Epirubicin—liver cancer	0.000192	0.00209	CcSEcCtD
Ezetimibe—Chest pain—Epirubicin—liver cancer	0.000192	0.00209	CcSEcCtD
Ezetimibe—Myalgia—Epirubicin—liver cancer	0.000192	0.00209	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00019	0.00208	CcSEcCtD
Ezetimibe—Discomfort—Epirubicin—liver cancer	0.000189	0.00207	CcSEcCtD
Ezetimibe—Malaise—Doxorubicin—liver cancer	0.000188	0.00205	CcSEcCtD
Ezetimibe—Dry mouth—Epirubicin—liver cancer	0.000187	0.00205	CcSEcCtD
Ezetimibe—ABCB1—liver—liver cancer	0.000186	0.00136	CbGeAlD
Ezetimibe—Confusional state—Epirubicin—liver cancer	0.000185	0.00202	CcSEcCtD
Ezetimibe—Palpitations—Doxorubicin—liver cancer	0.000184	0.00201	CcSEcCtD
Ezetimibe—Anaphylactic shock—Epirubicin—liver cancer	0.000184	0.00201	CcSEcCtD
Ezetimibe—Infection—Epirubicin—liver cancer	0.000182	0.00199	CcSEcCtD
Ezetimibe—Cough—Doxorubicin—liver cancer	0.000182	0.00199	CcSEcCtD
Ezetimibe—Nervous system disorder—Epirubicin—liver cancer	0.00018	0.00197	CcSEcCtD
Ezetimibe—Thrombocytopenia—Epirubicin—liver cancer	0.00018	0.00197	CcSEcCtD
Ezetimibe—Hypertension—Doxorubicin—liver cancer	0.00018	0.00197	CcSEcCtD
Ezetimibe—Skin disorder—Epirubicin—liver cancer	0.000178	0.00195	CcSEcCtD
Ezetimibe—Myalgia—Doxorubicin—liver cancer	0.000177	0.00194	CcSEcCtD
Ezetimibe—Arthralgia—Doxorubicin—liver cancer	0.000177	0.00194	CcSEcCtD
Ezetimibe—Chest pain—Doxorubicin—liver cancer	0.000177	0.00194	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000176	0.00192	CcSEcCtD
Ezetimibe—Discomfort—Doxorubicin—liver cancer	0.000175	0.00191	CcSEcCtD
Ezetimibe—Dry mouth—Doxorubicin—liver cancer	0.000173	0.0019	CcSEcCtD
Ezetimibe—Confusional state—Doxorubicin—liver cancer	0.000171	0.00187	CcSEcCtD
Ezetimibe—Anaphylactic shock—Doxorubicin—liver cancer	0.00017	0.00186	CcSEcCtD
Ezetimibe—Infection—Doxorubicin—liver cancer	0.000169	0.00185	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000167	0.00183	CcSEcCtD
Ezetimibe—Nervous system disorder—Doxorubicin—liver cancer	0.000167	0.00182	CcSEcCtD
Ezetimibe—Thrombocytopenia—Doxorubicin—liver cancer	0.000166	0.00182	CcSEcCtD
Ezetimibe—Insomnia—Epirubicin—liver cancer	0.000166	0.00182	CcSEcCtD
Ezetimibe—Skin disorder—Doxorubicin—liver cancer	0.000165	0.0018	CcSEcCtD
Ezetimibe—Paraesthesia—Epirubicin—liver cancer	0.000165	0.0018	CcSEcCtD
Ezetimibe—Dyspnoea—Epirubicin—liver cancer	0.000164	0.00179	CcSEcCtD
Ezetimibe—Dyspepsia—Epirubicin—liver cancer	0.000162	0.00177	CcSEcCtD
Ezetimibe—Decreased appetite—Epirubicin—liver cancer	0.00016	0.00175	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Epirubicin—liver cancer	0.000159	0.00173	CcSEcCtD
Ezetimibe—Fatigue—Epirubicin—liver cancer	0.000158	0.00173	CcSEcCtD
Ezetimibe—Pain—Epirubicin—liver cancer	0.000157	0.00172	CcSEcCtD
Ezetimibe—Constipation—Epirubicin—liver cancer	0.000157	0.00172	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000155	0.00169	CcSEcCtD
Ezetimibe—Insomnia—Doxorubicin—liver cancer	0.000154	0.00168	CcSEcCtD
Ezetimibe—Paraesthesia—Doxorubicin—liver cancer	0.000153	0.00167	CcSEcCtD
Ezetimibe—Dyspnoea—Doxorubicin—liver cancer	0.000152	0.00166	CcSEcCtD
Ezetimibe—Feeling abnormal—Epirubicin—liver cancer	0.000151	0.00165	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Epirubicin—liver cancer	0.00015	0.00164	CcSEcCtD
Ezetimibe—Dyspepsia—Doxorubicin—liver cancer	0.00015	0.00164	CcSEcCtD
Ezetimibe—Decreased appetite—Doxorubicin—liver cancer	0.000148	0.00162	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000147	0.0016	CcSEcCtD
Ezetimibe—Fatigue—Doxorubicin—liver cancer	0.000147	0.0016	CcSEcCtD
Ezetimibe—Urticaria—Epirubicin—liver cancer	0.000146	0.0016	CcSEcCtD
Ezetimibe—Pain—Doxorubicin—liver cancer	0.000145	0.00159	CcSEcCtD
Ezetimibe—Constipation—Doxorubicin—liver cancer	0.000145	0.00159	CcSEcCtD
Ezetimibe—Abdominal pain—Epirubicin—liver cancer	0.000145	0.00159	CcSEcCtD
Ezetimibe—Body temperature increased—Epirubicin—liver cancer	0.000145	0.00159	CcSEcCtD
Ezetimibe—Feeling abnormal—Doxorubicin—liver cancer	0.00014	0.00153	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Doxorubicin—liver cancer	0.000139	0.00152	CcSEcCtD
Ezetimibe—Hypersensitivity—Epirubicin—liver cancer	0.000135	0.00148	CcSEcCtD
Ezetimibe—Urticaria—Doxorubicin—liver cancer	0.000135	0.00148	CcSEcCtD
Ezetimibe—Body temperature increased—Doxorubicin—liver cancer	0.000134	0.00147	CcSEcCtD
Ezetimibe—Abdominal pain—Doxorubicin—liver cancer	0.000134	0.00147	CcSEcCtD
Ezetimibe—Asthenia—Epirubicin—liver cancer	0.000132	0.00144	CcSEcCtD
Ezetimibe—Pruritus—Epirubicin—liver cancer	0.00013	0.00142	CcSEcCtD
Ezetimibe—Diarrhoea—Epirubicin—liver cancer	0.000126	0.00137	CcSEcCtD
Ezetimibe—Hypersensitivity—Doxorubicin—liver cancer	0.000125	0.00137	CcSEcCtD
Ezetimibe—Asthenia—Doxorubicin—liver cancer	0.000122	0.00133	CcSEcCtD
Ezetimibe—Dizziness—Epirubicin—liver cancer	0.000121	0.00133	CcSEcCtD
Ezetimibe—Pruritus—Doxorubicin—liver cancer	0.00012	0.00131	CcSEcCtD
Ezetimibe—Vomiting—Epirubicin—liver cancer	0.000117	0.00128	CcSEcCtD
Ezetimibe—Diarrhoea—Doxorubicin—liver cancer	0.000116	0.00127	CcSEcCtD
Ezetimibe—Rash—Epirubicin—liver cancer	0.000116	0.00127	CcSEcCtD
Ezetimibe—Dermatitis—Epirubicin—liver cancer	0.000116	0.00126	CcSEcCtD
Ezetimibe—Headache—Epirubicin—liver cancer	0.000115	0.00126	CcSEcCtD
Ezetimibe—Dizziness—Doxorubicin—liver cancer	0.000112	0.00123	CcSEcCtD
Ezetimibe—Nausea—Epirubicin—liver cancer	0.000109	0.00119	CcSEcCtD
Ezetimibe—Vomiting—Doxorubicin—liver cancer	0.000108	0.00118	CcSEcCtD
Ezetimibe—Rash—Doxorubicin—liver cancer	0.000107	0.00117	CcSEcCtD
Ezetimibe—Dermatitis—Doxorubicin—liver cancer	0.000107	0.00117	CcSEcCtD
Ezetimibe—Headache—Doxorubicin—liver cancer	0.000106	0.00116	CcSEcCtD
Ezetimibe—Nausea—Doxorubicin—liver cancer	0.000101	0.0011	CcSEcCtD
Ezetimibe—CYP3A4—Biological oxidations—GSTP1—liver cancer	2.02e-05	0.000103	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—AKT1—liver cancer	2.01e-05	0.000103	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—EPT1—liver cancer	2e-05	0.000103	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CYCS—liver cancer	2e-05	0.000103	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2e-05	0.000103	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—ALB—liver cancer	2e-05	0.000102	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ALDOB—liver cancer	1.99e-05	0.000102	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PSMA4—liver cancer	1.99e-05	0.000102	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PSMD10—liver cancer	1.99e-05	0.000102	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PSMA4—liver cancer	1.99e-05	0.000102	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PSMD10—liver cancer	1.99e-05	0.000102	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	1.99e-05	0.000102	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CD—liver cancer	1.98e-05	0.000101	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GGT1—liver cancer	1.96e-05	0.000101	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GOT1—liver cancer	1.96e-05	0.000101	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—ALB—liver cancer	1.95e-05	0.0001	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTA1—liver cancer	1.95e-05	0.0001	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GOT2—liver cancer	1.94e-05	9.94e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GOT2—liver cancer	1.94e-05	9.94e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NAT2—liver cancer	1.93e-05	9.89e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CRABP1—liver cancer	1.9e-05	9.76e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—PPARA—liver cancer	1.9e-05	9.76e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—TAT—liver cancer	1.9e-05	9.75e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—ALB—liver cancer	1.9e-05	9.74e-05	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PIK3CA—liver cancer	1.86e-05	9.57e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—GSTM1—liver cancer	1.85e-05	9.51e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ALDOB—liver cancer	1.85e-05	9.48e-05	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	1.83e-05	9.41e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	1.83e-05	9.38e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYP2E1—liver cancer	1.82e-05	9.34e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP2E1—liver cancer	1.82e-05	9.34e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—HPGDS—liver cancer	1.81e-05	9.31e-05	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PIK3CA—liver cancer	1.79e-05	9.22e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GSTP1—liver cancer	1.77e-05	9.06e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.76e-05	9.05e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CRABP1—liver cancer	1.76e-05	9.04e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—PPARA—liver cancer	1.76e-05	9.04e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—CYP1A1—liver cancer	1.76e-05	9.02e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—HMOX1—liver cancer	1.74e-05	8.94e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	1.73e-05	8.89e-05	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CB—liver cancer	1.72e-05	8.85e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—RAF1—liver cancer	1.72e-05	8.81e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.71e-05	8.79e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYCS—liver cancer	1.7e-05	8.74e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYCS—liver cancer	1.7e-05	8.74e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GOT1—liver cancer	1.67e-05	8.58e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GGT1—liver cancer	1.67e-05	8.58e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GOT1—liver cancer	1.67e-05	8.58e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GGT1—liver cancer	1.67e-05	8.58e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—HPGDS—liver cancer	1.66e-05	8.53e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.65e-05	8.48e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—GSTM1—liver cancer	1.62e-05	8.33e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PSMD10—liver cancer	1.62e-05	8.3e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PSMA4—liver cancer	1.62e-05	8.3e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	1.61e-05	8.27e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GOT2—liver cancer	1.57e-05	8.08e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—HPGDS—liver cancer	1.54e-05	7.9e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CYP1A1—liver cancer	1.54e-05	7.89e-05	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—AKT1—liver cancer	1.52e-05	7.82e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.51e-05	7.73e-05	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	1.5e-05	7.72e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GSTP1—liver cancer	1.5e-05	7.71e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GSTP1—liver cancer	1.5e-05	7.71e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.49e-05	7.63e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PSMA4—liver cancer	1.48e-05	7.61e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PSMD10—liver cancer	1.48e-05	7.61e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—HMOX1—liver cancer	1.48e-05	7.6e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—HMOX1—liver cancer	1.48e-05	7.6e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP2E1—liver cancer	1.48e-05	7.59e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	1.48e-05	7.58e-05	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—AKT1—liver cancer	1.47e-05	7.53e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	1.45e-05	7.43e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GOT2—liver cancer	1.44e-05	7.4e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—MTHFR—liver cancer	1.43e-05	7.36e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—ALB—liver cancer	1.41e-05	7.25e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	1.41e-05	7.23e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPARA—liver cancer	1.41e-05	7.22e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	1.41e-05	7.21e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	1.39e-05	7.16e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYCS—liver cancer	1.38e-05	7.1e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—GSTM1—liver cancer	1.38e-05	7.08e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—GSTM1—liver cancer	1.38e-05	7.08e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PSMA4—liver cancer	1.37e-05	7.04e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PSMD10—liver cancer	1.37e-05	7.04e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	1.36e-05	6.99e-05	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	1.36e-05	6.99e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GGT1—liver cancer	1.36e-05	6.97e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GOT1—liver cancer	1.36e-05	6.97e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	1.36e-05	6.96e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP2E1—liver cancer	1.36e-05	6.96e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GOT2—liver cancer	1.33e-05	6.85e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	1.33e-05	6.83e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—UGDH—liver cancer	1.31e-05	6.74e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.31e-05	6.74e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—ALB—liver cancer	1.31e-05	6.72e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CYP1A1—liver cancer	1.31e-05	6.71e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CYP1A1—liver cancer	1.31e-05	6.71e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CPT1B—liver cancer	1.29e-05	6.63e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GLUL—liver cancer	1.29e-05	6.63e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—RAF1—liver cancer	1.28e-05	6.56e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYCS—liver cancer	1.27e-05	6.51e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP2E1—liver cancer	1.25e-05	6.44e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NR1H4—liver cancer	1.25e-05	6.39e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GGT1—liver cancer	1.24e-05	6.39e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GOT1—liver cancer	1.24e-05	6.39e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—EPT1—liver cancer	1.23e-05	6.34e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	1.23e-05	6.3e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTA3—liver cancer	1.22e-05	6.29e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GSTP1—liver cancer	1.22e-05	6.26e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—MTHFR—liver cancer	1.22e-05	6.26e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—MTHFR—liver cancer	1.22e-05	6.26e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CG—liver cancer	1.2e-05	6.18e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—HMOX1—liver cancer	1.2e-05	6.18e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPARA—liver cancer	1.2e-05	6.14e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPARA—liver cancer	1.2e-05	6.14e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—RAF1—liver cancer	1.18e-05	6.07e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	1.18e-05	6.05e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYCS—liver cancer	1.17e-05	6.03e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—TAT—liver cancer	1.17e-05	6.01e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPARG—liver cancer	1.16e-05	5.97e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GGT1—liver cancer	1.15e-05	5.91e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GOT1—liver cancer	1.15e-05	5.91e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.13e-05	5.8e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.13e-05	5.79e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—GSTM1—liver cancer	1.12e-05	5.75e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTA4—liver cancer	1.12e-05	5.75e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GSTP1—liver cancer	1.12e-05	5.74e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—HMOX1—liver cancer	1.1e-05	5.66e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTA2—liver cancer	1.09e-05	5.6e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.07e-05	5.51e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CYP1A1—liver cancer	1.06e-05	5.45e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CD—liver cancer	1.06e-05	5.44e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTA1—liver cancer	1.05e-05	5.41e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	1.05e-05	5.4e-05	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PIK3CA—liver cancer	1.05e-05	5.39e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—ALB—liver cancer	1.05e-05	5.37e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	1.04e-05	5.36e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NAT2—liver cancer	1.04e-05	5.34e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTP1—liver cancer	1.03e-05	5.31e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—GSTM1—liver cancer	1.03e-05	5.27e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CG—liver cancer	1.02e-05	5.26e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CG—liver cancer	1.02e-05	5.26e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—HMOX1—liver cancer	1.02e-05	5.24e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ALDOB—liver cancer	9.98e-06	5.12e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—MTHFR—liver cancer	9.9e-06	5.09e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPARG—liver cancer	9.88e-06	5.07e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPARG—liver cancer	9.88e-06	5.07e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CYP1A1—liver cancer	9.74e-06	5e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPARA—liver cancer	9.72e-06	4.99e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	9.59e-06	4.92e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CRABP1—liver cancer	9.52e-06	4.89e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	9.52e-06	4.89e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—GSTM1—liver cancer	9.51e-06	4.88e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	9.28e-06	4.76e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CB—liver cancer	9.23e-06	4.74e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—MTHFR—liver cancer	9.08e-06	4.66e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CYP1A1—liver cancer	9.01e-06	4.63e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CD—liver cancer	9e-06	4.62e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CD—liver cancer	9e-06	4.62e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPARA—liver cancer	8.9e-06	4.57e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—ALB—liver cancer	8.89e-06	4.56e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—ALB—liver cancer	8.89e-06	4.56e-05	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—AKT1—liver cancer	8.58e-06	4.41e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—MTHFR—liver cancer	8.4e-06	4.31e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CG—liver cancer	8.32e-06	4.27e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—HPGDS—liver cancer	8.32e-06	4.27e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPARA—liver cancer	8.24e-06	4.23e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPARG—liver cancer	8.03e-06	4.12e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8e-06	4.11e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CPT1B—liver cancer	7.96e-06	4.09e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GLUL—liver cancer	7.96e-06	4.09e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CB—liver cancer	7.85e-06	4.03e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CB—liver cancer	7.85e-06	4.03e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	7.83e-06	4.02e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NR1H4—liver cancer	7.67e-06	3.94e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CG—liver cancer	7.63e-06	3.92e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTA3—liver cancer	7.54e-06	3.87e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PSMD10—liver cancer	7.42e-06	3.81e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PSMA4—liver cancer	7.42e-06	3.81e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPARG—liver cancer	7.36e-06	3.78e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CD—liver cancer	7.32e-06	3.76e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—ALB—liver cancer	7.22e-06	3.71e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GOT2—liver cancer	7.22e-06	3.7e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	7.07e-06	3.63e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CG—liver cancer	7.06e-06	3.63e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTA4—liver cancer	6.9e-06	3.54e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPARG—liver cancer	6.81e-06	3.5e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP2E1—liver cancer	6.78e-06	3.48e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTA2—liver cancer	6.72e-06	3.45e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CD—liver cancer	6.7e-06	3.44e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—ALB—liver cancer	6.62e-06	3.4e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTA1—liver cancer	6.49e-06	3.33e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NAT2—liver cancer	6.41e-06	3.29e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	6.4e-06	3.28e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CB—liver cancer	6.38e-06	3.27e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYCS—liver cancer	6.35e-06	3.26e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GOT1—liver cancer	6.23e-06	3.2e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GGT1—liver cancer	6.23e-06	3.2e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CD—liver cancer	6.21e-06	3.19e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ALDOB—liver cancer	6.15e-06	3.16e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—ALB—liver cancer	6.13e-06	3.15e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CRABP1—liver cancer	5.87e-06	3.01e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CB—liver cancer	5.84e-06	3e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PIK3CA—liver cancer	5.63e-06	2.89e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTP1—liver cancer	5.59e-06	2.87e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—HMOX1—liver cancer	5.52e-06	2.83e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CB—liver cancer	5.41e-06	2.78e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—GSTM1—liver cancer	5.14e-06	2.64e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—HPGDS—liver cancer	5.13e-06	2.63e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CYP1A1—liver cancer	4.87e-06	2.5e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PIK3CA—liver cancer	4.78e-06	2.46e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PIK3CA—liver cancer	4.78e-06	2.46e-05	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—AKT1—liver cancer	4.6e-06	2.36e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PSMD10—liver cancer	4.57e-06	2.35e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PSMA4—liver cancer	4.57e-06	2.35e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—MTHFR—liver cancer	4.54e-06	2.33e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPARA—liver cancer	4.46e-06	2.29e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GOT2—liver cancer	4.45e-06	2.28e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP2E1—liver cancer	4.18e-06	2.15e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYCS—liver cancer	3.91e-06	2.01e-05	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—AKT1—liver cancer	3.91e-06	2.01e-05	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—AKT1—liver cancer	3.91e-06	2.01e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PIK3CA—liver cancer	3.89e-06	2e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GOT1—liver cancer	3.84e-06	1.97e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GGT1—liver cancer	3.84e-06	1.97e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CG—liver cancer	3.82e-06	1.96e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPARG—liver cancer	3.68e-06	1.89e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PIK3CA—liver cancer	3.56e-06	1.83e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTP1—liver cancer	3.45e-06	1.77e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—HMOX1—liver cancer	3.4e-06	1.75e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CD—liver cancer	3.36e-06	1.72e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—ALB—liver cancer	3.31e-06	1.7e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PIK3CA—liver cancer	3.3e-06	1.69e-05	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—AKT1—liver cancer	3.18e-06	1.63e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—GSTM1—liver cancer	3.17e-06	1.63e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CYP1A1—liver cancer	3e-06	1.54e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CB—liver cancer	2.93e-06	1.5e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—AKT1—liver cancer	2.91e-06	1.49e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—MTHFR—liver cancer	2.8e-06	1.44e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPARA—liver cancer	2.75e-06	1.41e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—AKT1—liver cancer	2.69e-06	1.38e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CG—liver cancer	2.35e-06	1.21e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPARG—liver cancer	2.27e-06	1.17e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CD—liver cancer	2.07e-06	1.06e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—ALB—liver cancer	2.04e-06	1.05e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CB—liver cancer	1.8e-06	9.25e-06	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PIK3CA—liver cancer	1.78e-06	9.16e-06	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—AKT1—liver cancer	1.46e-06	7.48e-06	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PIK3CA—liver cancer	1.1e-06	5.64e-06	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—AKT1—liver cancer	8.97e-07	4.61e-06	CbGpPWpGaD
